Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: Phenylethylamine HCl evidence and protocol review
Also known as: PEA HCl, beta-Phenylethylamine hydrochloride
Phenylethylamine (PEA) is an endogenous trace amine acting as a stimulant and dopaminergic/noradrenergic-releasing agent. It and its derivatives are listed on the WADA banned-substance list under section S6 (Stimulants). Research notes that regular food consumption does not yield sufficient phenylethylamine levels to result in an Adverse Analytical Finding, distinguishing incidental dietary exposure from supplemental/research dosing. Note: this compound (an amine stimulant) is chemically and functionally distinct from Palmitoylethanolamide (also sometimes abbreviated 'PEA' in casual usage), documented separately in this catalog as an anti-inflammatory lipid - the shared abbreviation is a common source of confusion that content should explicitly disambiguate.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.
No safe supplement protocol is established
Context: trace-amine pharmacology review
Formulation: Oral-mucosal formulations are not dose-equivalent to injectable or topical formulations.
Route safety: No route-specific protocol is established. Do not infer an amount from another route, component, or formulation.
Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.
Combining phenylethylamine with MAO inhibitors is a high-risk interaction, not a protocol; hypertensive and serotonergic/adrenergic toxicity are concerns.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.